Axsome Therapeutics akcijos akcijų analizė | Akcijų kaina | Naujienos | AXSM | US05464T1043 | A2AA7B

Data	Axsome Therapeutics Akcijų kaina
2024-09-19	94,32 undefined
2024-09-18	91,54 undefined
2024-09-17	90,94 undefined
2024-09-16	92,41 undefined
2024-09-13	93,67 undefined
2024-09-12	91,75 undefined
2024-09-11	91,03 undefined
2024-09-10	92,69 undefined
2024-09-09	94,09 undefined
2024-09-06	93,19 undefined
2024-09-05	93,69 undefined
2024-09-04	95,56 undefined
2024-09-03	89,65 undefined
2024-08-30	88,86 undefined
2024-08-29	89,11 undefined
2024-08-28	88,43 undefined
2024-08-27	88,93 undefined
2024-08-26	88,51 undefined
2024-08-23	87,99 undefined
2024-08-22	87,11 undefined

Data	Axsome Therapeutics Pajamos	Axsome Therapeutics EBIT	Axsome Therapeutics Pelnas
2029e	2,47 mlrd. undefined	0 undefined	854,51 mln. undefined
2028e	2,06 mlrd. undefined	1,34 mlrd. undefined	622,53 mln. undefined
2027e	1,62 mlrd. undefined	989,53 mln. undefined	411,75 mln. undefined
2026e	1,13 mlrd. undefined	362,30 mln. undefined	213,64 mln. undefined
2025e	652,75 mln. undefined	9,40 mln. undefined	−96,66 mln. undefined
2024e	385,61 mln. undefined	−225,17 mln. undefined	−271,55 mln. undefined
2023	270,60 mln. undefined	−231,83 mln. undefined	−239,24 mln. undefined
2022	50,04 mln. undefined	−179,30 mln. undefined	−187,13 mln. undefined
2021	0 undefined	−124,71 mln. undefined	−130,40 mln. undefined
2020	0 undefined	−99,14 mln. undefined	−102,90 mln. undefined
2019	0 undefined	−67,25 mln. undefined	−68,35 mln. undefined
2018	0 undefined	−32,85 mln. undefined	−30,97 mln. undefined
2017	0 undefined	−27,16 mln. undefined	−28,94 mln. undefined
2016	0 undefined	−27,54 mln. undefined	−27,20 mln. undefined
2015	0 undefined	−9,20 mln. undefined	−12,21 mln. undefined
2014	0 undefined	−5,67 mln. undefined	−6,00 mln. undefined
2013	0 undefined	−1,84 mln. undefined	−2,17 mln. undefined

	Pajamos	EBIT	Pelnas
2013	0 USD	−1,84 mln. USD	−2,17 mln. USD
2014	0 USD	−5,67 mln. USD	−6,00 mln. USD
2015	0 USD	−9,20 mln. USD	−12,21 mln. USD
2016	0 USD	−27,54 mln. USD	−27,20 mln. USD
2017	0 USD	−27,16 mln. USD	−28,94 mln. USD
2018	0 USD	−32,85 mln. USD	−30,97 mln. USD
2019	0 USD	−67,25 mln. USD	−68,35 mln. USD
2020	0 USD	−99,14 mln. USD	−102,90 mln. USD
2021	0 USD	−124,71 mln. USD	−130,40 mln. USD
2022	50,04 mln. USD	−179,30 mln. USD	−187,13 mln. USD
2023	270,60 mln. USD	−231,83 mln. USD	−239,24 mln. USD
2024e	385,61 mln. USD	−225,17 mln. USD	−271,55 mln. USD
2025e	652,75 mln. USD	9,40 mln. USD	−96,66 mln. USD
2026e	1,13 mlrd. USD	362,30 mln. USD	213,64 mln. USD
2027e	1,62 mlrd. USD	989,53 mln. USD	411,75 mln. USD
2028e	2,06 mlrd. USD	1,34 mlrd. USD	622,53 mln. USD
2029e	2,47 mlrd. USD	0 USD	854,51 mln. USD

2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
0	0	0	0	0	0	0	0	0	0,05	0,27	0,39	0,65	1,13	1,62	2,06	2,47
-	-	-	-	-	-	-	-	-	-	440,00	42,59	69,35	73,01	43,17	27,62	19,60
-	-	-	-	-	-	-	-	-	88,00	90,37	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	44,00	244,00	0	0	0	0	0	0
−0,00	−0,01	−0,01	−0,03	−0,03	−0,03	−0,07	−0,10	−0,12	−0,18	−0,23	−0,23	0,01	0,36	0,99	1,34	0
-	-	-	-	-	-	-	-	-	−358,00	−85,56	−58,44	1,38	32,09	61,24	64,82	-
−2,00	−6,00	−12,00	−27,00	−28,00	−30,00	−68,00	−102,00	−130,00	−187,00	−239,00	−271,00	−96,00	213,00	411,00	622,00	854,00
-	200,00	100,00	125,00	3,70	7,14	126,67	50,00	27,45	43,85	27,81	13,39	−64,58	−321,88	92,96	51,34	37,30
17,72	17,72	11,95	19,15	22,76	26,88	34,02	37,21	37,62	40,66	45,43	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

2,10	2,60	48,00	36,60	34,00	14,00	220,00	183,90	86,50	200,80	386,19
0	0	0	0	0	0	0	0	0	37,70	94,82
0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	4,30	15,14
0	0,10	1,00	1,40	1,30	1,20	0,40	0,10	0	2,80	8,12
2,10	2,70	49,00	38,00	35,30	15,20	220,40	184,00	86,50	245,60	504,26
0	0	0	0,10	0,10	0,10	0	1,80	0,90	1,10	7,62
0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	59,70	53,29
0	0	0	0	0	0	0	0	0	10,30	12,04
0	0	0	0,10	0,20	0,10	0,10	0,30	0,30	14,70	11,03
0	0	0	0,20	0,30	0,20	0,10	2,10	1,20	85,80	83,97
2,10	2,70	49,00	38,20	35,60	15,40	220,50	186,10	87,70	331,40	588,24

0	0	0	0	0	0	0	0	0	0	5,00
0,00	0,01	0,07	0,07	0,09	0,11	0,35	0,39	0,42	0,71	1,03
−2,20	−8,20	−20,40	−47,60	−76,60	−107,60	−175,90	−278,80	−409,20	−596,30	−835,57
0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0
−2,00	−3,20	46,50	21,60	16,70	0,90	178,70	113,80	15,60	109,60	190,98
0,20	0,80	1,90	4,10	3,40	3,70	10,90	13,50	13,10	38,60	40,68
0,10	0	0,70	2,80	2,70	3,80	10,90	9,90	9,90	52,10	91,77
0	0,10	0	0	2,80	0	0	0	0	5,90	6,41
100,00	0	0	0	0	0	0	0	0	0	0
3,80	0	0	0,30	3,30	3,30	2,60	0	0	0	0
4,20	0,90	2,60	7,20	12,20	10,80	24,40	23,40	23,00	96,60	138,85
0	4,40	0	9,50	6,70	3,60	17,30	48,30	49,10	94,30	178,07
0	0	0	0	0	0	0	0	0	0	0
0	0,60	0	0	0	0	0	0,60	0	31,10	80,34
0	5,00	0	9,50	6,70	3,60	17,30	48,90	49,10	125,40	258,41
4,20	5,90	2,60	16,70	18,90	14,40	41,70	72,30	72,10	222,00	397,26
2,20	2,70	49,10	38,30	35,60	15,30	220,40	186,10	87,70	331,60	588,24

2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
−2,00	−6,00	−10,00	−27,00	−28,00	−30,00	−68,00	−102,00	−130,00	−187,00	−239,00
0	0	0	0	0	0	0	0	0	4,00	6,00
0	0	0	0	0	0	0	0	0	0	0
0	0	0	3,00	0	1,00	15,00	0	0	22,00	−28,00
0	1,00	2,00	4,00	5,00	1,00	12,00	38,00	43,00	81,00	178,00
0	0	0	0	0	0	1,00	2,00	4,00	7,00	16,00
0	0	0	0	0	0	0	0	0	0	0
−1,00	−4,00	−7,00	−21,00	−26,00	−30,00	−46,00	−78,00	−108,00	−116,00	−145,00
0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	−53,00	0
0	0	0	0	0	0	0	0	0	−53,00	0
0	0	0	0	0	0	0	0	0	0	0
3,00	5,00	7,00	10,00	0	−3,00	12,00	28,00	0	45,00	85,00
0	0	45,00	0	24,00	13,00	239,00	15,00	11,00	243,00	271,00
3,00	5,00	52,00	9,00	23,00	10,00	252,00	42,00	11,00	284,00	331,00
-	-	-	-	-	-	-	−1,00	-	−3,00	−25,00
0	0	0	0	0	0	0	0	0	0	0
2,00	0	45,00	−11,00	−2,00	−20,00	205,00	−36,00	−97,00	114,00	185,00
−1,63	−4,60	−7,46	−21,38	−26,48	−30,08	−46,40	−78,51	−108,54	−117,21	−145,66
0	0	0	0	0	0	0	0	0	0	0

Axsome Therapeutics Bruto marža	Axsome Therapeutics Pelnas-martža	Axsome Therapeutics EBIT marža	Axsome Therapeutics Pelnas-martža
2029e	90,37 %	0 %	34,65 %
2028e	90,37 %	64,82 %	30,21 %
2027e	90,37 %	61,27 %	25,50 %
2026e	90,37 %	32,09 %	18,92 %
2025e	90,37 %	1,44 %	−14,81 %
2024e	90,37 %	−58,39 %	−70,42 %
2023	90,37 %	−85,67 %	−88,41 %
2022	89,61 %	−358,31 %	−373,96 %
2021	90,37 %	0 %	0 %
2020	90,37 %	0 %	0 %
2019	90,37 %	0 %	0 %
2018	90,37 %	0 %	0 %
2017	90,37 %	0 %	0 %
2016	90,37 %	0 %	0 %
2015	90,37 %	0 %	0 %
2014	90,37 %	0 %	0 %
2013	90,37 %	0 %	0 %

	Bruto marža	EBIT marža	Pelnas-martža
2013	90,37 %	0 %	0 %
2014	90,37 %	0 %	0 %
2015	90,37 %	0 %	0 %
2016	90,37 %	0 %	0 %
2017	90,37 %	0 %	0 %
2018	90,37 %	0 %	0 %
2019	90,37 %	0 %	0 %
2020	90,37 %	0 %	0 %
2021	90,37 %	0 %	0 %
2022	89,61 %	−358,31 %	−373,96 %
2023	90,37 %	−85,67 %	−88,41 %
2024e	90,37 %	−58,39 %	−70,42 %
2025e	90,37 %	1,44 %	−14,81 %
2026e	90,37 %	32,09 %	18,92 %
2027e	90,37 %	61,27 %	25,50 %
2028e	90,37 %	64,82 %	30,21 %
2029e	90,37 %	0 %	34,65 %

Data	Axsome Therapeutics Pardavimai vienai akcijai	Axsome Therapeutics EBIT vienai akcijai	Axsome Therapeutics Pelnas vienai akcijai
2029e	51,37 undefined	0 undefined	17,80 undefined
2028e	42,94 undefined	0 undefined	12,97 undefined
2027e	33,65 undefined	0 undefined	8,58 undefined
2026e	23,52 undefined	0 undefined	4,45 undefined
2025e	13,60 undefined	0 undefined	−2,01 undefined
2024e	8,03 undefined	0 undefined	−5,66 undefined
2023	5,96 undefined	−5,10 undefined	−5,27 undefined
2022	1,23 undefined	−4,41 undefined	−4,60 undefined
2021	0 undefined	−3,31 undefined	−3,47 undefined
2020	0 undefined	−2,66 undefined	−2,77 undefined
2019	0 undefined	−1,98 undefined	−2,01 undefined
2018	0 undefined	−1,22 undefined	−1,15 undefined
2017	0 undefined	−1,19 undefined	−1,27 undefined
2016	0 undefined	−1,44 undefined	−1,42 undefined
2015	0 undefined	−0,77 undefined	−1,02 undefined
2014	0 undefined	−0,32 undefined	−0,34 undefined
2013	0 undefined	−0,10 undefined	−0,12 undefined

	Pardavimai vienai akcijai	EBIT vienai akcijai	Pelnas vienai akcijai
2013	0 USD	−0,10 USD	−0,12 USD
2014	0 USD	−0,32 USD	−0,34 USD
2015	0 USD	−0,77 USD	−1,02 USD
2016	0 USD	−1,44 USD	−1,42 USD
2017	0 USD	−1,19 USD	−1,27 USD
2018	0 USD	−1,22 USD	−1,15 USD
2019	0 USD	−1,98 USD	−2,01 USD
2020	0 USD	−2,66 USD	−2,77 USD
2021	0 USD	−3,31 USD	−3,47 USD
2022	1,23 USD	−4,41 USD	−4,60 USD
2023	5,96 USD	−5,10 USD	−5,27 USD
2024e	8,03 USD	0 USD	−5,66 USD
2025e	13,60 USD	0 USD	−2,01 USD
2026e	23,52 USD	0 USD	4,45 USD
2027e	33,65 USD	0 USD	8,58 USD
2028e	42,94 USD	0 USD	12,97 USD
2029e	51,37 USD	0 USD	17,80 USD

	Akcijų skaičius
2013	17,72 mln. Aktien
2014	17,72 mln. Aktien
2015	11,95 mln. Aktien
2016	19,15 mln. Aktien
2017	22,76 mln. Aktien
2018	26,88 mln. Aktien
2019	34,02 mln. Aktien
2020	37,21 mln. Aktien
2021	37,62 mln. Aktien
2022	40,66 mln. Aktien
2023	45,43 mln. Aktien
2024e	45,43 mln. Aktien
2025e	45,43 mln. Aktien
2026e	45,43 mln. Aktien
2027e	45,43 mln. Aktien
2028e	45,43 mln. Aktien
2029e	45,43 mln. Aktien

Data	EPS-prognozė	EPS-Faktinis	Pranešimo ketvirtis
2024-06-30	−1,36	−1,67 (−22,88 %)	2024 Q2
2024-03-31	−1,23	−1,44 (−17,22 %)	2024 Q1
2023-12-31	−1,19	−2,08 (−74,12 %)	2023 Q4
2023-09-30	−1,23	−1,32 (−7,52 %)	2023 Q3
2023-06-30	−1,25	−1,54 (−23,51 %)	2023 Q2
2023-03-31	−1,06	−0,26 (75,39 %)	2023 Q1
2022-12-31	−1,16	−1,41 (−21,43 %)	2022 Q4
2022-09-30	−1,10	−1,07 (2,80 %)	2022 Q3
2022-06-30	−1,23	−1,06 (13,98 %)	2022 Q2
2022-03-31	−1,02	−1,03 (−0,75 %)	2022 Q1
2021-12-31	−1,04	−0,90 (13,63 %)	2021 Q4
2021-09-30	−0,97	−0,93 (4,06 %)	2021 Q3
2021-06-30	−0,98	−0,86 (12,63 %)	2021 Q2
2021-03-31	−0,88	−0,78 (11,83 %)	2021 Q1
2020-12-31	−0,77	−0,78 (−0,91 %)	2020 Q4
2020-09-30	−0,58	−0,58 (0,62 %)	2020 Q3
2020-06-30	−0,63	−0,49 (22,07 %)	2020 Q2
2020-03-31	−0,64	−0,88 (−38,17 %)	2020 Q1
2019-12-31	−0,49	−0,71 (−45,02 %)	2019 Q4
2019-09-30	−0,41	−0,56 (−36,82 %)	2019 Q3
2019-06-30	−0,33	−0,41 (−23,05 %)	2019 Q2
2019-03-31	−0,30	−0,32 (−6,00 %)	2019 Q1
2018-12-31	−0,30	−0,32 (−5,44 %)	2018 Q4
2018-09-30	−0,29	−0,31 (−6,02 %)	2018 Q3
2018-06-30	−0,30	−0,32 (−6,35 %)	2018 Q2
2018-03-31	−0,29	−0,19 (33,47 %)	2018 Q1
2017-12-31	−0,32	−0,31 (3,52 %)	2017 Q4
2017-09-30	−0,35	−0,27 (22,15 %)	2017 Q3
2017-06-30	−0,34	−0,30 (12,64 %)	2017 Q2
2017-03-31	−0,40	−0,41 (−3,07 %)	2017 Q1
2016-12-31	−0,43	−0,40 (5,88 %)	2016 Q4
2016-09-30	−0,40	−0,38 (4,47 %)	2016 Q3
2016-06-30	−0,40	−0,36 (9,50 %)	2016 Q2
2016-03-31	−0,28	−0,31 (−10,52 %)	2016 Q1
2015-12-31	−0,22	−0,12 (46,52 %)	2015 Q4

%	Pavadinimas	Akcijos	Pokytis	Data
9,35333 %	RTW Investments L.P.	4 489 596	0	2023-12-31
7,68756 %	The Vanguard Group, Inc.	3 690 027	−32 360	2023-12-31
5,83802 %	BlackRock Institutional Trust Company, N.A.	2 802 249	267 537	2023-12-31
4,91683 %	Fairmount Funds Management LLC	2 360 077	0	2024-02-14
4,12729 %	BVF Partners L.P.	1 981 100	−150 000	2023-12-31
2,26893 %	Citadel Advisors LLC	1 089 085	−206 539	2023-12-31
2,16254 %	Perceptive Advisors LLC	1 038 019	556 370	2023-12-31
2,08333 %	Deep Track Capital LP	1 000 000	−140 745	2023-12-31
2,08333 %	RA Capital Management, LP	1 000 000	0	2023-12-31
15,30104 %	Antecip Capital, L.L.C.	7 344 500	0	2023-04-10
1,92540 %	State Street Global Advisors (US)	924 190	56 543	2023-12-31
1,89576 %	Millennium Management LLC	909 965	406 923	2023-12-31
1,74417 %	Point72 Asset Management, L.P.	837 201	305 264	2023-12-31
1,71313 %	Geode Capital Management, L.L.C.	822 304	43 809	2023-12-31
1,56676 %	Alethea Capital Management, LLC	752 044	−6 750	2023-12-31
1,45611 %	Pictet Asset Management Ltd.	698 932	52 503	2023-12-31
1,32369 %	Bellevue Asset Management AG	635 372	3 885	2023-12-31
1,17361 %	Jefferies LLC	563 335	10 140	2023-12-31
1,17117 %	Woodline Partners LP	562 163	110 056	2023-12-31
1,12677 %	Fidelity Management & Research Company LLC	540 849	−981 224	2023-12-31
0,97381 %	PFM Health Sciences, LP	467 427	−55 783	2023-12-31
0,95708 %	Avidity Partners Management LP	459 400	162 600	2023-12-31
0,93234 %	Coleman (Mark H)	447 525	0	2023-09-15
0,83333 %	Boxer Capital, L.L.C.	400 000	0	2023-12-31
0,81824 %	Hood River Capital Management LLC	392 753	9 477	2023-12-31
0,76179 %	Morgan Stanley & Co. LLC	365 660	314 379	2023-12-31
0,76042 %	Adage Capital Management, L.P.	365 000	40 000	2023-12-31
0,72232 %	Eventide Asset Management, LLC	346 712	0	2023-12-31
0,71079 %	Fidelity Institutional Asset Management	341 178	4 695	2023-12-31
0,66667 %	Tang Capital Management, LLC	320 000	0	2023-12-31
0,64997 %	Northern Trust Investments, Inc.	311 985	8 356	2023-12-31
0,61604 %	Charles Schwab Investment Management, Inc.	295 701	5 830	2023-12-31
0,61548 %	First Turn Management, LLC	295 428	295 428	2023-12-31
0,55384 %	Driehaus Capital Management, LLC	265 842	16 953	2023-12-31
0,49962 %	Wellington Management Company, LLP	239 819	2 265	2023-12-31
0,48599 %	Nuveen LLC	233 273	16 950	2023-12-31
0,44164 %	Morgan Stanley Smith Barney LLC	211 986	7 285	2023-12-31
0,40651 %	Norges Bank Investment Management (NBIM)	195 123	−61 274	2023-12-31
0,39971 %	Barclays Bank PLC	191 862	175 164	2023-12-31
0,34931 %	Jeffs (Roger A)	167 668	0	2024-03-15
0,34375 %	Ghost Tree Capital, LLC	165 000	55 000	2023-12-31
0,33445 %	BofA Global Research (US)	160 534	136 659	2023-12-31
0,32554 %	Goldman Sachs & Company, Inc.	156 261	48 311	2023-12-31
0,32364 %	Checkpoint Capital L.P.	155 346	155 346	2023-12-31
0,31950 %	BlackRock Asset Management Ireland Limited	153 360	−6 457	2023-12-31
0,30379 %	BlackRock Advisors (UK) Limited	145 817	−1 580	2024-03-31
0,30057 %	BlackRock Financial Management, Inc.	144 273	38 954	2023-12-31
0,29880 %	U.S. Bancorp Asset Management, Inc.	143 424	4 653	2023-12-31
0,29132 %	Loomis, Sayles & Company, L.P.	139 832	139 832	2024-02-29
0,28820 %	Iridian Asset Management LLC	138 337	−6 696	2023-12-31
0,28750 %	Altium Capital Management LP	138 000	46 000	2023-12-31
0,27237 %	Tri Locum Partners LP	130 738	−11 772	2023-12-31
0,26810 %	JP Morgan Asset Management	128 688	−24 497	2023-12-31
0,25539 %	T. Rowe Price Associates, Inc.	122 586	115 719	2023-12-31
0,24790 %	Medical Strategy GmbH	118 990	−4 300	2023-12-31
0,22259 %	Schonfeld Strategic Advisors LLC	106 842	39 144	2023-12-31
0,21963 %	BNY Mellon Asset Management	105 421	230	2023-12-31
0,21835 %	WCM Investment Management	104 808	8 845	2023-12-31
0,21193 %	Citi Investment Research (US)	101 727	−935	2023-12-31
0,21013 %	Ally Bridge Group NY LLC	100 862	−9 738	2023-12-31
0,19768 %	Frontier Capital Management Company, LLC	94 888	−65 788	2023-12-31
0,19456 %	BioImpact Capital LLC	93 387	−199	2023-12-31
0,19340 %	Jane Street Capital, L.L.C.	92 831	−32 750	2023-12-31
0,18427 %	BlackRock Investment Management, LLC	88 450	1 660	2023-12-31
0,18302 %	Artia Global Partners LP	87 848	0	2023-12-31
0,17726 %	Candriam Belgium S.A.	85 084	35 000	2023-12-31
0,17670 %	Peregrine Capital Management, LLC	84 817	−6 274	2023-12-31
0,17518 %	Lindbrook Capital, LLC	84 086	−233	2023-12-31
0,17259 %	Cannell & Co.	82 845	−21 345	2023-12-31
0,17218 %	Nicholas Investment Partners, L.P.	82 645	−312 335	2023-12-31
0,16758 %	HSBC Global Asset Management (UK) Limited	80 437	−68 375	2023-12-31
0,16479 %	Rhenman & Partners Asset Management AB	79 100	39 000	2023-12-31
0,16436 %	Jess S. Morgan & Company, Inc	78 895	−25 994	2022-09-30
0,15643 %	Candriam Luxembourg S.A.	75 084	0	2024-02-29
0,15208 %	ACT Capital Management, L.L.C.	73 000	73 000	2022-09-30
0,15007 %	Privium Fund Management BV	72 032	0	2023-12-31
0,14564 %	First Trust Advisors L.P.	69 909	794	2023-12-31
0,14476 %	Hennion & Walsh Asset Management, Inc.	69 483	8 867	2024-03-31
0,13930 %	Moody Aldrich Partners, LLC	66 866	−6 767	2023-12-31
0,13896 %	Atika Capital Management LLC	66 700	−4 300	2023-12-31
0,12971 %	HighVista Strategies LLC	62 263	5 299	2023-12-31
0,12604 %	Schweizerische Nationalbank	60 500	−11 200	2023-12-31
0,12583 %	ClearBridge Investments, LLC	60 400	60 400	2024-03-31
0,12146 %	International Biotechnology Trust PLC	58 300	0	2023-09-30
0,12146 %	Schroder Investment Management Ltd. (SIM)	58 300	58 300	2023-12-31
0,11709 %	Lighthouse Partners	56 202	56 202	2023-12-31
0,11181 %	DWS Investment Management Americas, Inc.	53 670	10 661	2023-12-31
0,10565 %	WMS Partners LLC	50 711	−30 000	2023-12-31
0,10549 %	Rhumbline Advisers Ltd. Partnership	50 637	−208	2023-12-31
0,10417 %	Affinity Asset Advisors LLC	50 000	50 000	2023-12-31
0,10353 %	Baldwin Brothers, LLC.	49 695	700	2024-03-31
0,10324 %	Goldman Sachs Asset Management, L.P.	49 554	−1 745	2023-12-31
0,10203 %	Mellon Investments Corporation	48 976	−1 886	2023-12-31
0,09476 %	Putnam Investment Management, L.L.C.	45 486	−74 780	2023-12-31
0,09319 %	Invesco Advisers, Inc.	44 733	−16 436	2023-12-31
0,09232 %	Neuberger Berman, LLC	44 315	40 050	2023-12-31
0,08965 %	Credit Suisse Funds AG	43 033	182	2023-12-31
0,08808 %	Pizzie (Nick)	42 277	0	2023-04-10
0,08602 %	AllianceBernstein L.P.	41 290	0	2023-12-31
0,08359 %	UBS Financial Services, Inc.	40 125	7 341	2023-12-31

What values and corporate philosophy does Axsome Therapeutics represent?

Axsome Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders. The company's core values revolve around advancing the treatment options for patients suffering from CNS conditions such as major depressive disorder, Alzheimer's disease, and narcolepsy. Axsome Therapeutics Inc is committed to rigorous research and development to deliver breakthrough medicines that improve patients' lives. With a strong corporate philosophy centered on scientific excellence, patient-centricity, and a dedication to healthcare innovation, Axsome Therapeutics Inc aims to address unmet medical needs and make a lasting impact in the field of CNS disorders.

In which countries and regions is Axsome Therapeutics primarily present?

Axsome Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Axsome Therapeutics achieved?

Axsome Therapeutics Inc has achieved several significant milestones. The company successfully received FDA approval for its product, which has shown promising results in clinical trials. Additionally, Axsome Therapeutics Inc has established strategic partnerships with key industry players and has expanded its product pipeline to target various medical conditions. Moreover, the company has successfully raised funding from renowned investors, enabling it to further advance its research and development efforts. Axsome Therapeutics Inc continues to make significant progress in the field of therapeutic treatments and is dedicated to improving the lives of patients.

What is the history and background of the company Axsome Therapeutics?

Axsome Therapeutics Inc is a renowned biopharmaceutical company with a rich history and background. Founded in 2012, Axsome is dedicated to developing innovative therapies to improve the lives of patients suffering from central nervous system (CNS) disorders. The company focuses on areas such as depression, Alzheimer's disease, migraines, and other related conditions. Axsome Therapeutics Inc has a diverse pipeline of potential treatments and utilizes cutting-edge research and clinical trials to drive their drug development process. With a steadfast commitment to improving patient outcomes, Axsome Therapeutics Inc is emerging as a key player in the field of CNS therapeutics.

Who are the main competitors of Axsome Therapeutics in the market?

The main competitors of Axsome Therapeutics Inc in the market include pharmaceutical companies such as Sage Therapeutics, Zosano Pharma Corporation, and Marinus Pharmaceuticals. Axsome Therapeutics Inc develops innovative treatments for central nervous system (CNS) disorders, focusing on difficult-to-treat conditions. With its unique product pipeline and research-driven approach, Axsome competes with these companies in developing novel therapeutics for CNS disorders.

In which industries is Axsome Therapeutics primarily active?

Axsome Therapeutics Inc is primarily active in the pharmaceutical industry.

What is the business model of Axsome Therapeutics?

The business model of Axsome Therapeutics Inc is focused on developing and commercializing innovative therapies for neurological disorders. The company aims to address unmet medical needs and improve the lives of patients by advancing its pipeline of potential treatments. Axsome Therapeutics Inc utilizes a strategic approach that includes clinical development, regulatory approvals, and collaboration with healthcare professionals and regulatory agencies. With a strong commitment to research and development, Axsome Therapeutics Inc seeks to provide effective therapies that can make a substantial impact in the field of neurology.

Koks yra Axsome Therapeutics 2024 KGV?

Axsome Therapeutics KGV yra −15,78.

Koks Axsome Therapeutics 2024 KUV?

Axsome Therapeutics KUV yra 11,11.

Koks yra Axsome Therapeutics AlleAktien kokybės įvertinimas?

AlleAktien kokybės įvertis Axsome Therapeutics yra 5/10.

Koks yra Axsome Therapeutics 2024 pajamų dydis?

tikėtina Axsome Therapeutics pardavimai yra 385,61 mln. USD.

Kokia yra Axsome Therapeutics 2024 pelnas?

tikėtina Axsome Therapeutics pelnas yra −271,55 mln. USD.

Ką daro Axsome Therapeutics?

Axsome Therapeutics Inc is a publicly-traded biopharmaceutical company based in New York City that develops effective and safe therapies for patients with severe neurological disorders. The company primarily focuses on developing treatments for patients with depression, schizophrenia, Alzheimer's disease, fibromyalgia, and other serious neurological disorders. Axsome's business model is based on developing innovative therapies for patients that are currently not available on the market or have limited effectiveness. The company utilizes a combination of proprietary technologies and partnerships with leading academic institutions to develop these therapies. Axsome Therapeutics has focused on developing medications tailored to the needs of patients who cannot find appropriate treatment elsewhere. The company has successfully advanced its clinical development programs and demonstrated the potential to introduce new therapies for difficult-to-treat patients. Axsome Therapeutics has several products in clinical trials, including AXS-05, an NMDA receptor antagonist currently being developed for the treatment of depression and Alzheimer's disease. The company also has AXS-07, a new migraine medication, AXS-12 for the treatment of cataplexy in patients with narcolepsy, and AXS-14 for the treatment of fibromyalgia in clinical trials. To operate its business model successfully, Axsome Therapeutics utilizes a wide range of partnerships and distribution channels. The company works closely with academic centers and other industry leaders to evaluate and develop innovative solutions for difficult-to-treat patients. Additionally, Axsome Therapeutics collaborates with a number of strategic partners, including specialized CROs (contract research organizations) and distribution partners, to collect safety and efficacy data for its development programs and develop marketing strategies. Finally, Axsome Therapeutics also leverages the benefits of digital technologies to optimize its business model and improve access to its therapies. The company utilizes modern digital platforms to raise awareness among patients suffering from the diseases they treat about their clinical trials. This way, Axsome Therapeutics can potentially recruit more patients for their clinical trials and bring their therapeutics to market faster. In summary, Axsome Therapeutics Inc is an innovative biopharmaceutical company that focuses on developing therapies for difficult-to-treat diseases. The company utilizes a combination of proprietary technologies, strategic partnerships, and digital marketing to optimize its business model and successfully advance its development programs. With several products in clinical trials and a strong pipeline, Axsome Therapeutics is well-positioned to drive both patient well-being and company growth.

Kokia yra Axsome Therapeutics dividendė?

Axsome Therapeutics moka dividendą 0 USD, kuris yra paskirstytas per išmokas per metus.

Kiek kartų Axsome Therapeutics moka dividendą?

Dividenda šiuo metu negali būti apskaičiuota Axsome Therapeutics arba įmonė dividendų nemoka.

Kas yra Axsome Therapeutics ISIN?

Axsome Therapeutics ISIN yra US05464T1043.

Kas yra Axsome Therapeutics WKN?

Axsome Therapeutics WKN yra A2AA7B.

Kas yra Axsome Therapeutics Tickeris?

Axsome Therapeutics akcijų simbolis yra AXSM.

Kiek dividendų moka Axsome Therapeutics?

Per paskutinius 12 mėnesių Axsome Therapeutics išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Axsome Therapeutics tikėtina išmokės dividendus, kurie sudarys 0 USD.

Kokia yra Axsome Therapeutics dividendų grąža?

Axsome Therapeutics šiuo metu yra dydžio dividendų grąža.

Kada Axsome Therapeutics moka dividendus?

Axsome Therapeutics moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Kokia saugi yra Axsome Therapeutics dividendų išmokėjimas?

Axsome Therapeutics per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Kokia yra Axsome Therapeutics dividendų suma?

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 USD. Tai atitinka 0 % dividendų grąžos procentą.

Kokiame sektoriuje yra Axsome Therapeutics?

Axsome Therapeutics priskiriamas sektoriui "Sveikata".

Wann musste ich die Aktien von Axsome Therapeutics kaufen, um die vorherige Dividende zu erhalten?

Norėdamas gauti paskutinį Axsome Therapeutics dividendą nuo 2024-09-20, kurio dydis yra 0 USD, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-09-20.

Kada Axsome Therapeutics paskutinį kartą mokėjo dividendą?

Paskutinės dividendų išmokėjimas įvyko 2024-09-20.

Kokia buvo Axsome Therapeutics dividendų suma 2023 metais?

2023 metais Axsome Therapeutics išmokėjo 0 USD dividendų.

Kokia valiuta Axsome Therapeutics moka dividendus?

Axsome Therapeutics dividendai yra mokami USD.

Tiesioginiai išleidimai	—
Netiesioginės emisijos iš įsigytos energijos	—
Tiesioginiai išmetimai iš vertybių grandinės	—
CO₂ emisijos	—
CO₂ mažinimo strategija	✅
Anglies energija	❌
Atomkraft	❌
Bandymai su gyvūnais	✅
Pelz & Leder	—
Pesticidai	—
Palmių aliejus	—
Tabakas	❌
Genetinė inžinerija	❌
Klimato koncepcija	—
Tvarioji miškininkystė	—
Perdirbimo nuostatai	❌
Aplinkai draugiška pakuotė	❌
Pavojingosios medžiagos	❌
Degalų sąnaudos ir efektyvumas	❌
Vandens suvartojimas ir efektyvumas	❌

Moterų dalis tarp darbuotojų	—
Moterų dalis valdyme	—
Azijietiškų darbuotojų dalis	—
Akcijų dalis Azijos valdyme	—
Hispanų/lotynų kilmės darbuotojų dalis	—
Hispanų/latino kilmės vadybos dalis	—
Akcijų turimų tamsios odos darbuotojų procentas	—
Juodaodžių valdymo dalis	—
Baltųjų darbuotojų dalis	—
Baltųjų valdymo dalis	—
Suaugusiųjų turinys	❌
Alkoholis	❌
Ginkluotė	—
Šaunamieji ginklai	❌
Azartiniai lošimai	❌
Karinių sutarčių	❌
Žmogaus teisių koncepcija	❌
Privatumo politika	—
Darbo ir sveikatos apsauga	✅
Katalikiškas	✅

Tvarumo ataskaita	❌
Akcijų turėtojų įtraukimas	❌
Atsiliepimo taisyklės	❌
Kartelio teisė	❌

Birža	Axsome Therapeutics Akcijų kodas
DIUSELDORFAS	19X.DU
FRANKFURTAS	19X.F
LONDON	0HKF.L
LONDON STOCK EXCHANGE	0HKF.L
MIUNCHENAS	19X.MU
NASDAQ	AXSM

Axsome Therapeutics Akcijų kodas	Axsome Therapeutics FIGI
AXSM:US	BBG00B6G7GL7
AXSM:UA	BBG00B6G7GN5
AXSM:UC	BBG00B6G7GP3
AXSM:UN	BBG00B6G7GR1
AXSM:UP	BBG00B6G7GS0
AXSM:UQ	BBG00B6G7GT9
AXSM:UB	BBG00B6G7GV6
AXSM:UM	BBG00B6G7GX4
AXSM:UX	BBG00B6G7GY3
AXSM:UD	BBG00B6G7H35
AXSM:UF	BBG00B6G7H62
AXSM:VY	BBG00B6G7H71
AXSM:VJ	BBG00B6G7H80
AXSM:VK	BBG00B6G7H99
AXSM:VF	BBG00DJH1TC5
19X:GR	BBG00GHB1C58
19X:GF	BBG00GHB1C67
19X:GD	BBG00GHB1C76
19X:GM	BBG00GHB1CB1
19X:GB	BBG00GHB1CD9
AXSMEUR:EO	BBG00GK9RTN4
AXSMEUR:XH	BBG00GK9RTR0
AXSMEUR:XF	BBG00GK9RTT8
AXSMEUR:XE	BBG00GK9RTW4
AXSMEUR:XJ	BBG00GK9RTX3
AXSMEUR:XL	BBG00GK9RTY2
AXSMEUR:XG	BBG00GK9RTZ1
AXSMEUR:XO	BBG00GK9RV04
AXSMEUR:XS	BBG00GK9RV40
AXSMEUR:XA	BBG00GK9RV59
AXSMEUR:E1	BBG00GK9RV68
AXSMEUR:XT	BBG00GK9RV77
AXSMEUR:XW	BBG00GK9RV86
AXSMEUR:XU	BBG00GK9RV95
AXSMEUR:XV	BBG00GK9RVB2
AXSMEUR:EU	BBG00GK9RVD0
AXSMEUR:XX	BBG00JN8LZ86
AXSMUSD:X2	BBG00JQ50677
AXSMUSD:XB	BBG00JQ50686
AXSMUSD:XH	BBG00JQ506B2
AXSMUSD:XF	BBG00JQ506D0
AXSMUSD:XE	BBG00JQ506G7
AXSMUSD:XJ	BBG00JQ506H6
AXSMUSD:XL	BBG00JQ506J4
AXSMUSD:XG	BBG00JQ506K2
AXSMUSD:XO	BBG00JQ506L1
AXSMUSD:XS	BBG00JQ506Q6
AXSMUSD:XA	BBG00JQ506R5
AXSMUSD:E1	BBG00JQ506S4
AXSMUSD:XT	BBG00JQ506T3
AXSMUSD:XW	BBG00JQ506V0
AXSMUSD:XU	BBG00JQ506W9
AXSMUSD:XV	BBG00JQ506X8
AXSMUSD:XM	BBG00JQ506Y7
AXSMUSD:XQ	BBG00JQ50702
AXSMUSD:XX	BBG00JQ50711
AXSMUSD:XZ	BBG00JQ50720
AXSMUSD:EU	BBG00JQ50748
0HKF:LN	BBG00JVRN7V9
AXSMGBX:XS	BBG00L332V20
AXSMGBX:XH	BBG00L332V57
AXSMGBX:XF	BBG00L332V75
AXSMGBX:XE	BBG00L332V93
AXSMGBX:XJ	BBG00L332VB0
AXSMGBX:XL	BBG00L332VC9
AXSMGBX:XG	BBG00L332VD8
AXSMGBX:XO	BBG00L332VF6
AXSMGBX:XA	BBG00L332VK0
AXSMGBX:E1	BBG00L332VL9
AXSMGBX:XT	BBG00L332VM8
AXSMGBX:XW	BBG00L332VN7
AXSMGBX:XU	BBG00L332VP5
AXSMGBX:XV	BBG00L332VQ4
AXSMGBX:XM	BBG00L332VR3
AXSMGBX:B1	BBG00L332VS2
AXSMGBX:XQ	BBG00L332VT1
AXSMGBX:XX	BBG00L332VV8
AXSMGBX:XZ	BBG00L332VW7
AXSMGBX:EU	BBG00L332VY5
19X:TH	BBG00N0W6CB3
19X:GZ	BBG00R0Y7G84
AXSM:VG	BBG00X1PBCD7
AXSM:VP	BBG00X1SRRS5
AXSM*:MM	BBG012N09JP0
AXSM*:MF	BBG012N09JQ9
19X:QT	BBG0141H8WB0
19X:LA	BBG018H9HT47
19X:LU	BBG018J34TW1

Padaryk geriausias savo gyvenimo investicijas fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Kursas

Akcijos kaina

Akcijų kodasAXSM

ISINUS05464T1043

VVPA2AA7B

Axsome Therapeutics akcijų kaina

Kursas

Apžvalga

Intraday funkcija

Bendroji grąža ir santykinė kainų pokyčiai

Interpretacija ir investavimas

Axsome Therapeutics Akcijų istorija

Axsome Therapeutics akcijų apyvarta, EBIT, pelnas US05464T1043 · A2AA7B

Pajamos, pelnas & EBIT

Supratimas apie pajamas, EBIT ir pelną

Metinė analizė ir palyginimai

Išnaudoti lūkesčius investuojant

Investicijų įžvalgos

Axsome Therapeutics Pajamų, pelno ir EBIT istorija.

Axsome Therapeutics Akcijų rodikliai

GuV

Pajamos ir augimas

Bruto marža

EBIT ir EBIT marža

Pajamos ir jų augimas

Leidžiamų akcijų skaičius

Metinių duomenų palyginimo interpretacija

Lūkesčiai ir prognozės

Balansas

Balanso supratimas

Turtas

Įsipareigojimai

Nuosavas kapitalas

Metų po metų analizė

Duomenų interpretacija

Axsome Therapeutics Akcijos Maržos US05464T1043 · A2AA7B

Margen

Supratimas apie bruto maržą

EBIT maržos analizė

Pardavimų maržos įžvalgos

Lūkesčių interpretavimas

Lyginamoji analizė

Axsome Therapeutics Maržų istorija

Axsome Therapeutics akcijos apyvarta, EBIT, pelnas vienai akcijai US05464T1043 · A2AA7B

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Axsome Therapeutics Pardavimų, pelno ir EBIT istorija vienai akcijai

Axsome Therapeutics akcija ir akcijų analizė

Axsome Therapeutics vertinimas pagal Fair Value

Fair Value

Supratimas apie Fair Value

Pajamų pagrindu skaičiuojamas Fair Value

Apyvartos pagrindu skaičiuojamas Fair Value

Dividendų pagrindu skaičiuojamas Fair Value

Lūkesčiai ir prognozės

Palyginamoji analizė

Axsome Therapeutics įvertinimas pagal istorinį P/E, EBIT ir P/S

Axsome Therapeutics akcijų skaičius US05464T1043 · A2AA7B

Pardavimai, EBIT ir Pelnas vienai akcijai

Pajamos vienai akcijai

EBIT vienai akcijai

Pelnas vienai akcijai

Tikėtinos vertės

Axsome Therapeutics Pelno prognozės

Axsome Therapeutics Pelnų staigmenos

Eulerpool ESG reitingas Axsome Therapeutics akcijai

Eulerpool World ESG Rating (EESG©)

13/ 100

🌱 Environment

👫 Social

🏛️ Governance

Aplinka (Environment)

Socialinis (Social)

Įmonės valdymas (Governance)

Axsome Therapeutics akcijos akcininkų struktūra

Axsome Therapeutics Valdyba ir Priežiūros taryba

Padaryk geriausias savo gyvenimo investicijas
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Akcijų kodas
AXSM

ISIN
US05464T1043

VVP
A2AA7B